Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTS-GC: Adjuvant TS-1 for Gastric Cancer
NCT00152217Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2001
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur in gastric cancer (GC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall Survival at 5 years. Started Sep 2001; status: completed.
02
Drugs
tegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00152217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152217.